SCHEMBL13309050

SCHEMBL13309050

Bc1cnn2c(Nc3ccc(S(=O)(=O)Nc4ccccc4)cc3)cc(-c3ccccc3)nc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.47
▸ TSHR P16473 1/20 0.47
▸ MAPK1 P28482 1/20 0.47
▸ KDM4E B2RXH2 4/20 0.45
▸ TP53 P04637 1/20 0.45
▸ POLB P06746 1/20 0.45
▸ GSK3B P49841 2/20 0.45
▸ PKM P14618 3/20 0.45
▸ KMT2A Q03164 7/20 0.42
▸ MEN1 O00255 6/20 0.42
▸ MAPT P10636 6/20 0.42
▸ GAA P10253 2/20 0.42
▸ LMNA P02545 2/20 0.42
▸ NPC1 O15118 1/20 0.42
▸ HPGD P15428 1/20 0.42
▸ CLK1 P49759 1/20 0.42
▸ RAB9A P51151 1/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ CYP1A2 P05177 1/20 0.42
▸ CYP3A4 P08684 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14528871 0.95 KDM4E (0.43) ALDH1A1TSHRMAPK1KDM4ETP53
SCHEMBL13309486 0.90 KDM4E (0.56) ALDH1A1TSHRMAPK1KDM4ETP53
SCHEMBL13885078 0.88 GSK3B (0.59) ALDH1A1TSHRMAPK1KDM4ETP53
SCHEMBL13309082 0.88 GSK3B (0.46) ALDH1A1TSHRMAPK1KDM4ETP53
SCHEMBL13893805 0.88 GSK3B (0.48) ALDH1A1TSHRMAPK1KDM4ETP53
SCHEMBL14528951 0.87 KDM4E (0.45) ALDH1A1TSHRMAPK1KDM4ETP53
SCHEMBL13308747 0.87 KDM4E (0.44) ALDH1A1TSHRMAPK1KDM4ETP53
SCHEMBL13309221 0.85 KDM4E (0.44) ALDH1A1TSHRMAPK1KDM4ETP53
SCHEMBL13309321 0.85 CDK2 (0.42) ALDH1A1TSHRMAPK1KDM4ETP53
SCHEMBL14528735 0.84 KDM4E (0.43) ALDH1A1TSHRMAPK1KDM4ETP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1934224-B1 PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS FOR THE TREATMENT OF CANCER SCHERING CORP (US) 2010-06-09 — — EP disclosed
Send feedback